A snippet from one of press release slides on Q1 14 by Dr Reddys:
Global Generics : US
Market Share – Key Products
•Fondaparinux market share 29% (May-13) from 27%(Mar-13)
•Retaining share in other key products- tacrolimus, lansoprazole , ziprazidone and omeprazole DR (Source : IMS volumes)
•New product launch – Zoledronic acid market share ~30% for both the variants individually
•Finasteride (FTF) market Share: 81% (Source : IMS Rx)
- Forums
- ASX - By Stock
- TSN
- reddys q1 results
reddys q1 results, page-2
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online